Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study
Technology in Cancer Research & Treatment · 2023
DOI: 10.1177/15330338231165866 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2023. Verfasst von Yuanxin Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First People's Hospital of Lianyungang, Lianyungang, China. Hauptthemen laut MEDLINE: Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kangda College of Nanjing Medical University.
Abstract (Originalsprache)
Introduction
Central nervous system leukemia (CNSL) is the most common extramedullary relapse site in patients with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL), with a poor prognosis and high relapse rate.
Methods
We characterized the clinical data of 21 Ph-positive B-ALL patients to analyze the efficacy and safety of ponatinib for patients with central nervous system relapsed Ph-positive ALL retrospectively.
Results
There were 11 males and 10 females in the cohort, and their median age was 45 (9-58) years old. The total CR (complete remission) rate was 90.5%. All 9 patients achieved CR in the ponatinib group, and 10 patients achieved CR in the dasatinib group (100% vs 83.3%, respectively; P = .486) and minimal residual disease-positive CR in the ponatinib group and dasatinib group (88.9% vs 58.3%, P = .178). The medium time after achieving CR was 5 and 8 weeks ( P = .047). The total median overall survival (OS) was 31.1 months, and the 3-year OS was 49.0%. The median relapse-free survival (RFS) was 31.0 months, and the 3-year RFS was 45.2%. Patients in the ponatinib group showed a significantly longer OS than those patients in the dasatinib group with (medium OS not reached vs 27.6 months, P = .045) or without (medium OS not reached vs 27.6 months, P = .039) T315I mutations. The median RFS between the ponatinib group and the dasatinib group with T315I was not reached and 16.2 months, P = .065. The median RFS between the ponatinib group and the dasatinib group without T315I was not reached and 16.2 months, P = .036. No treatment-related deaths were observed during the therapy.
Conclusion
(1) Ph-positive CNSL patients seemed to have a high rate of response and postinduction MRD negativity with ponatinib and dasatinib, but ponatinib seemed to show a shorter time to achieve remission than dasatinib. (2) Ponatinib maintenance treatment might show superior survival for Ph-positive CNSL patients with or without the T315I mutation. (3) Ponatinib and dasatinib seemed to be both safe for the clinical application of Ph-positive CNSL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First People's Hospital of Lianyungang, Lianyungang, China.
- First Affiliated Hospital, Kangda College of Nanjing Medical University, Lianyungang, China.
- Department of Hematology, Jiangdu People's Hospital of Yangzhou, Yangzhou, China.
Förderung
- Kangda College of Nanjing Medical University
Zitieren
APA
Zhu, Y., Zhu, Y., Miao, L., Jia, T., Mao, J., Xue, L., & Wang, Y. (2023). Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338231165866
Vancouver
Zhu Y, Zhu Y, Miao L, Jia T, Mao J, Xue L, et al. Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study. Technology in Cancer Research & Treatment. 2023. doi:10.1177/15330338231165866
BibTeX
@article{Zhu2023,
author = {Zhu, Yuanxin and Zhu, Ying and Miao, Lei and Jia, Tao and Mao, Jianping and Xue, Lianguo and Wang, Ying},
title = {Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study},
journal = {Technology in Cancer Research & Treatment},
year = {2023},
doi = {10.1177/15330338231165866}
}
EUVIMED